![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 58, Issue 4, 828-836, October 2000
Departments of Pharmacology (C.H., F.T., B.M.M., E.G.E.) and
Anesthesiology (F.T., E.G.E), University of Illinois College of
Medicine at Chicago, Chicago, Illinois
Bradykinin (BK) and kallidin (Lys-BK), liberated from kininogens
by kallikreins, are ligands of the BK B2 receptor. We
investigated whether kallikreins, besides releasing peptide agonist,
could also activate the receptor directly. We studied the effect of porcine and human recombinant tissue kallikrein and plasma kallikrein on [Ca2+]i mobilization and
[3H]arachidonic acid release from cultured cells stably
transfected to express human BK B2 receptor
(CHO/B2, MDCK/B2, HEK/B2), and endothelial cells were used as control cells. As with BK, the actions of kallikrein were blocked by the B2 antagonist,
HOE 140. Kallikrein was inactive on cells lacking B2
receptor. Kallikrein and BK desensitized the receptor homologously but
there was no cross-desensitization. Furthermore, 50 nM human cathepsin
G and 50 nM trypsin also activated the receptor; this also was blocked by HOE 140. Experiments excluded a putative kinin release by proteases. [3H]AA release by BK was reduced by 40% by added
kininase I (carboxypeptidase M); however, receptor activation by tissue
kallikrein, trypsin, or cathepsin G was not affected. Prokallikrein and
inhibited kallikrein were inactive, suggesting cleavage of a peptide
bond in the receptor. Kallikreins were active on mutated B2
receptor missing the 19 N-terminal amino acids, suggesting a type of
activation different from that of thrombin receptor. Paradoxically,
tissue kallikreins decreased the [3H]BK binding to the
receptor with a low KD (3 nM) and inhibited it 78%. Thus, kallikreins and some other proteases activate human BK
B2 receptor directly, independent of BK release. The BK
B2 receptor may belong to a new group of serine
protease-activated receptors.
This article has been cited by other articles:
|
|
 |
|
  J. Chao, H. Yin, L. Gao, M. Hagiwara, B. Shen, Z.-R. Yang, and L. Chao Tissue Kallikrein Elicits Cardioprotection by Direct Kinin B2 Receptor Activation Independent of Kinin Formation Hypertension, October 1, 2008; 52(4): 715 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J Dietze and E. J Henriksen Review: Angiotensin-converting enzyme in skeletal muscle: sentinel of blood pressure control and glucose homeostasis Journal of Renin-Angiotensin-Aldosterone System, June 1, 2008; 9(2): 75 - 88. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Messadi-Laribi, V. Griol-Charhbili, A. Pizard, M.-P. Vincent, D. Heudes, P. Meneton, F. Alhenc-Gelas, and C. Richer Tissue Kallikrein Is Involved in the Cardioprotective Effect of AT1-Receptor Blockade in Acute Myocardial Ischemia J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 210 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hecquet, D. Biyashev, F. Tan, and E. G. Erdos Positive cooperativity between the thrombin and bradykinin B2 receptors enhances arachidonic acid release Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H948 - H958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Biyashev, F. Tan, Z. Chen, K. Zhang, P. A. Deddish, E. G. Erdos, and C. Hecquet Kallikrein activates bradykinin B2 receptors in absence of kininogen Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1244 - H1250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Picard, M. Van Abel, C. Campone, M. Seiler, M. Bloch-Faure, J. G.J. Hoenderop, J. Loffing, P. Meneton, R. J.M. Bindels, M. Paillard, et al. Tissue Kallikrein-Deficient Mice Display a Defect in Renal Tubular Calcium Absorption J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3602 - 3610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, F. Tan, E. G. Erdos, and P. A. Deddish Hydrolysis of Angiotensin Peptides by Human Angiotensin I-Converting Enzyme and the Resensitization of B2 Kinin Receptors Hypertension, December 1, 2005; 46(6): 1368 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sokolova, Z. Grishina, F. Buhling, T. Welte, and G. Reiser Protease-activated receptor-1 in human lung fibroblasts mediates a negative feedback downregulation via prostaglandin E2 Am J Physiol Lung Cell Mol Physiol, May 1, 2005; 288(5): L793 - L802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Kang, K. Ryberg, M. Morgelin, and L. M. F. Leeb-Lundberg Spontaneous Formation of a Proteolytic B1 and B2 Bradykinin Receptor Complex with Enhanced Signaling Capacity J. Biol. Chem., May 21, 2004; 279(21): 22102 - 22107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Borgono, I. P. Michael, and E. P. Diamandis Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Deddish, C. Hecquet, E. G. Erdos, F. Marceau, S. Houle, G. Molinaro, and A. Adam B2R of Bradykinin Activated by Proteases * Response: Does the Bradykinin B2 Receptor Function as a Protease-Activated Receptor? Hypertension, August 1, 2003; e2(2): . [Full Text] [PDF]
|
|
|
|
|
|
V. Thongboonkerd, E. Gozal, L. R. Sachleben Jr., J. M. Arthur, W. M. Pierce, J. Cai, J. Chao, M. Bader, J. B. Pesquero, D. Gozal, et al. Proteomic Analysis Reveals Alterations in the Renal Kallikrein Pathway during Hypoxia-Induced Hypertension J. Biol. Chem., September 13, 2002; 277(38): 34708 - 34716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Kang and L. M. F. Leeb-Lundberg Negative and Positive Regulatory Epitopes in the C-Terminal Domains of the Human B1 and B2 Bradykinin Receptor Subtypes Determine Receptor Coupling Efficacy to G9/11-Mediated Phospholipase Cbeta Activity Mol. Pharmacol., August 1, 2002; 62(2): 281 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Coy, N. Taneja, I. Lee, C. Hecquet, J. M. Bryson, and R. B. Robey LPA is a novel lipid regulator of mesangial cell hexokinase activity and HKII isoform expression Am J Physiol Renal Physiol, August 1, 2002; 283(2): F271 - F279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Trabold, S. Pons, A. A. Hagege, M. Bloch-Faure, F. Alhenc-Gelas, J.-F. Giudicelli, C. Richer-Giudicelli, and P. Meneton Cardiovascular Phenotypes of Kinin B2 Receptor- and Tissue Kallikrein-Deficient Mice Hypertension, July 1, 2002; 40(1): 90 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G Erdos Kinins, the long march--A personal view Cardiovasc Res, June 1, 2002; 54(3): 485 - 491. [Full Text] [PDF]
|
|
|
|
|
|
A. Valenzuela-Fernandez, T. Planchenault, F. Baleux, I. Staropoli, K. Le-Barillec, D. Leduc, T. Delaunay, F. Lazarini, J.-L. Virelizier, M. Chignard, et al. Leukocyte Elastase Negatively Regulates Stromal Cell-derived Factor-1 (SDF-1)/CXCR4 Binding and Functions by Amino-terminal Processing of SDF-1 and CXCR4 J. Biol. Chem., May 3, 2002; 277(18): 15677 - 15689. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
